Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
eNq1mFFv2jAQx9/5FFHeSQilrEyBamPthtSqrC3atBdkkgPMUjs920D36ecQqtLJUVcHPyZ2/nfx/f3zyfH59iHz1oCCctb3o6Dle8ASnlK26PuT+8vmmX8+aMQrsiYv09p6XhBFvpdkRIi+X4wGMyBMBD+vr76A/h7QHzS8mM9WkMhX85SkWfCNiOU1yYs5XrzmNPUeQC552vdzJXdvvVhI1FkMNhx/i5wkEIf7N4ejq2nn8H0cFmL/oaoE4BVhC6MoMCvNRCECk0MiYcHxqSLfEyttKm5BcIUJjIlcjpGvaQqpMcScZAKsgsw36R3gOgNZBDGKh6vkQViJkxXZ3sLjyJz0Jz06lFvZbDWjD2edbqvXO+lEra5VKDxYKnMV9E+EybTbaZ+22pb1GHOUJHNUCSqGr83kKA7C45sVT6nIM/IUrERuu1QEiR4G1Fve3Y8Uf3CPGkKZXrN/9JnKsvCdWU/2iHCUcUGgIVdMVpBicme7EEPOJGyrK2oHN7nde5GCOJ7sH87MYB+rWUYTW4xp0CgQcnI7qqZYXQB8JgIm6I4APyhL+UYcnyyHlXSUfb6Do1E0xzSatntn3ej01Hrj/NK2qThJLhTyHELNHCrqoGTE5rwuRLQTzVLPPqxlwV0PwxOSQUUX07RkiPbec9PlzN3udk45YBT9enFva4nvCvDpbvdolKZpv1YxExfQ1v6rzPv9bi43tZP2VqEZFkspc/ExDDebTbAkoimIXqVgjkcB+ME56a6hdnIYl81JCUFHqc/K0+19VbHdXG8d13Vb0P33+1bXGEOighq1KDnsjJaji+MD+KX/dJb2+BUx3IXZ9YpEUs5c9TNqZlSsSaARu0TNh5v5nFbcb1TaMg7Lu5VBIw6Le5VB4y9HdtL4
hHydXHgDtt6D3PQe
